Premium
Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy
Author(s) -
Lazzarotto Davide,
Candoni Anna,
Nadali Gianpaolo,
Pavan Laura,
Lessi Federica,
Mosna Federico,
Simeone Erica,
Ventura Giovanna,
Gherlinzoni Filippo,
Semenzato Gianpietro,
Pizzolo Giovanni,
Fanin Renato
Publication year - 2016
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12635
Subject(s) - medicine , myeloid leukaemia , induction chemotherapy , adverse effect , multivariate analysis , population , chemotherapy , epidemiology , surgery , environmental health
Background Acute myeloid leukaemia not responsive to first induction chemotherapy ( PIF ‐ AML ) still remains a challenge, and there are only few recent epidemiological data regarding the outcome of these patients. In this multicentre survey, we evaluate the prognosis and outcome of patients with PIF ‐ AML , who were diagnosed and treated in the last 5 yrs in four Italian institutions. Results One hundred PIF ‐ AML were recorded, 57 males and 43 females, with a median age of 63 yrs (19–79), 42% were younger than 60 yrs; 42% had a secondary AML and 40% had an adverse karyotype. According to cytogenetic/molecular risk stratification at diagnosis, 33% of patients were classified as favourable/intermediate‐1 risk and 56% as intermediate‐ 2 /adverse risk. After a median follow‐up of 11 months (1–49), 77% of patients died, while 23% were alive (with 12/23 in cCR ). Thirty‐six patients underwent allogeneic SCT , and of these, 11 of 36 (31%) were alive at last follow‐up. The 12‐ and 24‐month OS probability of the whole population was 45% and 21%, respectively. In multivariate analysis, the probability of OS of the whole population was significantly improved by Allo‐ SCT procedure (12‐month OS probability 60% vs. 35%; P < 0.0001) and was better in patients with favourable/intermediate‐1 risk at diagnosis (12‐month OS probability 58% vs. 40%; P = 0.028). In transplanted cases, a pretransplant responsive disease was the only significant factor to predict a favourable outcome after Allo‐ SCT ( P = 0.006). Conclusion Treatment options of PIF ‐ AML still are limited and the prognosis, even recently, remains extremely poor. This survey shows that PIF ‐ AML is still rarely cured without Allo‐ SCT and confirms the importance of initiating an urgent unrelated donor search in cases without a matched sibling donor. Moreover, the outcome of Allo‐ SCT is better in patients who achieve a good AML debulking before transplant. To reach this goal, new predictive scores and new protocols of salvage therapy (with target drugs or combinations) need to be explored urgently in PIF ‐ AML .